title: Cardiotoxicity due to cancer therapy.
abstract: The convergence of novel molecular techniques for the study of cardiovascular disease—together with the development of an armamentarium of molecular-targeted anticancer therapies—is fueling the interest of molecular cardiologists in probing the mechanisms of cancer-therapy–induced cardiac toxicity. Such studies have the potential to develop strategies that will prevent cardiac toxicity from becoming a barrier to effective anticancer therapy. They might also provide novel insights into the pathogenesis of non-cancer-therapy–induced human heart disease.
authors: Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. aykhakoo@mdanderson.org
authors: Aarif Y
authors: AY
authors: Khakoo
authors: Peter P
authors: PP
authors: Liu
authors: Thomas
authors: T
authors: Force
authors: Gabriel
authors: G
authors: Lopez-Berestein
authors: Lee W
authors: LW
authors: Jones
authors: Jay
authors: J
authors: Schneider
authors: Joseph
authors: J
authors: Hill
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents